EU Grants Marketing Authorization to AstraZeneca's Imfinzi
September 24 2018 - 11:57AM
Dow Jones News
By Dimitrios Kontos
AstraZeneca PLC (AZN.LN) said Monday that the European
Commission has granted marketing authorization for its Imfinzi
cancer treatment.
The EU has authorized Imfinzi as monotherapy for the treatment
of locally-advanced, unresectable non-small-cell lung cancer,
AstraZeneca said.
Imfinzi is the only immunotherapy to be approved in this
setting, the pharmaceutical company said.
The approval follows the positive opinion on July 27 from the
Committee for Medicinal Products for Human Use of the European
Medicines Agency.
Write to Dimitrios Kontos at dimitrios.kontos@dowjones.com
(END) Dow Jones Newswires
September 24, 2018 11:42 ET (15:42 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
